Results 121 to 130 of about 9,532 (171)

Real-World Treatment Patterns and Physician Perspectives in Relapsed/Refractory Multiple Myeloma: Results From a Nationwide Italian GIMEMA Survey. [PDF]

EJHaem
Fazio F, Piciocchi A, de Fabritiis P, Messina M, Soddu S, Sargentini V, Di Raimondo F, Patriarca F, Musto P, Offidani M, Zamagni E, Bringhen S, Gentile M, Mele G, Fazi P, Petrucci M, Cavo M.   +16 more
europepmc   +1 more source

Synergistic targeting of the ARID2-MYC axis by pomalidomide and panobinostat overcomes intrinsic IMiD resistance in multiple myeloma. [PDF]

Sci Rep
Yamamoto J, Asatsuma-Okumura T, Ito T, Iwai Y, Handa H, Yamaguchi Y.   +5 more
europepmc   +1 more source

A novel clip treatment for gastrointestinal bleeding in hereditary hemorrhagic telangiectasia. [PDF]

Endoscopy
Chan R, Karunadasa H, O'Connor R, Lai M, Urquhart P.   +4 more
europepmc   +1 more source

A real-time FRET ubiquitin transfer assay for quantitative characterization of ternary complexes in targeted protein degradation. [PDF]

Cell Rep Methods
Yu CH, Dougherty V, Lv D, Ebadi P, Dubey S, Nayak D, Nayak A, Zhou D, Olsen SK, Ivanov DN.   +9 more
europepmc   +1 more source

Management of relapsed/refractory AL amyloidosis. [PDF]

Blood Adv
Ling J, Sidiqi MH, Gertz M.
europepmc   +1 more source

Targeting BCMA in patients with relapsed/refractory multiple myeloma in 1 to 3 prior lines of therapy. [PDF]

Blood Adv
Hansen DK, Mateos MV, Costa LJ.
europepmc   +1 more source

Triazenyl Furans as Diels-Alder Dienes. [PDF]

J Am Chem Soc
Budwitz JE, Hollers SA, Wester AR, Newton CG.   +3 more
europepmc   +1 more source

The synthetic landscape of cereblon (CRBN) binders: from thalidomide to emerging chemotypes.

Chem Soc Rev
Rafael S, Sánchez-Zarzalejo C, Whelan R, Harris C, Verdaguer X, Mayor-Ruiz C, Riera A.   +6 more
europepmc   +1 more source

Central nervous system multiple myeloma: An update for 2026. [PDF]

Ann Hematol
Wang B, Li W, Liu M, Zhou H, Jin X, Wang W, Ge S, Gao W.   +7 more
europepmc   +1 more source